Investigational drug · Phase 2
Q702
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "Q702"
First trial start
2023
Jan 12, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Q702", any sponsor or status.
Conditions studied
As listed on its trial records.
- Esophageal Cancer
- Gastric Cancer
- Hepatocellular Cancer
- Cervical Cancer
Approved drugs for the same conditions: Stomach and esophageal cancer · Cervical cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Q702" as an intervention, largest first.
- Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid TumorsActive, not recruiting
Qurient Co., Ltd.Industry
NCT05438420 · 120 participants (planned) · Start Jan 12, 2023 · Primary completion Dec 30, 2027
Drug: Q702; Pembrolizumab · For: Esophageal Cancer; Gastric Cancer; Hepatocellular Cancer and 1 more
Sites: Los Angeles, California; Louisville, Kentucky; Seongnam-si, South Korea · 7 sites in all
- Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid TumorCompleted
Qurient Co., Ltd.Industry
NCT04648254 · 51 participants · Start Nov 18, 2020 · Primary completion Dec 23, 2025
Drug: Q702 · For: Solid Tumor; Advanced Cancer; Metastatic Cancer
Sites: Los Angeles, California; Chicago, Illinois; Morristown, New Jersey · 4 sites in all
Mayo ClinicAcademic, hospital or other
NCT06712810 · 46 participants (planned) · Start Aug 27, 2025 · Primary completion Sep 15, 2030
Drug: Axl/Mer/CSF1R Inhibitor Q702 · For: Hematopoietic and Lymphatic System Neoplasm; Histiocytic Sarcoma; Malignant Histiocytosis and 34 more
Sites: Scottsdale, Arizona; Rochester, Minnesota
- A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host DiseaseRecruiting
Qurient Co., Ltd.Industry
NCT07138196 · 18 participants (planned) · Start Dec 23, 2025 · Primary completion Oct 23, 2029
Drug: Adrixetinib · For: Chronic Graft-Versus-Host Disease
Sites: Barcelona, Spain; Madrid, Spain; Majadahonda, Spain · 8 sites in all
- Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT06445907 · 17 participants · Start Feb 12, 2025 · Primary completion Jul 1, 2027
Drug: Azacitidine; Venetoclax and 1 more · For: Acute Myeloid Leukemia
Sites: Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
- A Novel Selective Axl/Mer/CSF1R Kinase Inhibitor as a Cancer Immunotherapeutic Agent Targeting Both Immune and Tumor Cells in the Tumor Microenvironment.
Jeon Y, Kang H, Yang Y, et al. · Cancers (Basel) 2022
Also in development for Esophageal Cancer
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- Tegafur-gimeracil-oteracil potassiumS-1, tegafurPhase 38 trials
Ono Pharmaceutical Co., Ltd. · Gastric Cancer, Esophageal Cancer, Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
- AZD0901Sonesitatug vedotin, CMG901Phase 36 trials
AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma
- PetosemtamabMCLA-158, GEN1158Phase 35 trials
Genmab · Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Advanced/Metastatic Solid Tumors
- [18F]FAPI-74 PETPhase 33 trials
SOFIE · Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction
- LerotinibZ650Phase 31 trial
Sunshine Lake Pharma Co., Ltd. · Esophageal Cancer
- SI-B003Phase 210 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
- TQB6411Phase 22 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Advanced Lung Cancer, Esophageal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.